Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Radiother. 2012 Jul-Aug;16(4):282-7. doi: 10.1016/j.canrad.2012.03.008. Epub 2012 Jun 20.

[Extramedullary plasmocytomas].

[Article in French]

Author information

  • 1Service de radiothérapie carcinologique, CHU Habib-Bourguiba, Sfax, Tunisie. ben_salah_hanen@yahoo.fr

Abstract

PURPOSE:

To study the localization, treatment and prognosis of extramedullary plasmocytoma through a series of eight patients and a literature review.

PATIENTS AND METHODS:

Eight patients with extramedullary plasmocytoma were treated in the university's hospital of Sfax in Tunisia. The average age was 57.3 years. Female represented 75% of patients. The diagnosis of plasmocytoma was based on anatomo-pathology and immunohistochemistry of a biopsy or resected tumour. Extramedullary location was confirmed if biological and radiological exams and medullary biopsy were normal. The therapeutic decision was made after multidisciplinary meetings regarding tumour location and anterior treatment.

RESULTS:

Solitary extramedullary plasmocytoma was located in nasal cavity, cervical node, testis, ovary, bladder and the tongue. One patient was treated for three simultaneous locations of extramedullary plamocytoma (node, bowel, pleura) without evidence of myeloma. Radiotherapy was proposed in six cases but refused in one case (plasmocytoma of the bladder is currently receiving radiotherapy). Treatment consisted in chemotherapy in two cases. Evaluation after treatment revealed complete remission in 86% of the cases. Nodal recurrence was noted in two cases. These two patients were lost to follow up. The five other patients were in complete remission after a mean follow up of 5.7 years. No local recurrence or myeloma was noted.

CONCLUSION:

Extramedullary plasmocytoma is a rare affection. It can occur in any region of the body. Head and neck is most frequent localization. The treatment is irradiation or surgery in some localization. Progression to myeloma is the most important factor that influences the prognosis of the disease.

Copyright © 2012 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

PMID:
22726537
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk